Frontiers of anticoagulation therapy for atrial fibrillation

Journal of Cardiology

Volumn 58, Issue 1, 2011, Pages 1-5

  Yamashita, Takeshi ^a  

^a THE CARDIOVASCULAR INSTITUTE   (Japan)

Author keywords

Anticoagulant; Atrial fibrillation; Dabigatran; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR; DABIGATRAN; EDOXABAN; RIVAROXABAN; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANXIETY; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; DIET RESTRICTION; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG INTERACTION; DRUG SAFETY; DRUG UTILIZATION; EVIDENCE BASED MEDICINE; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; JAPAN; PATIENT IDENTIFICATION; PRESCRIPTION; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SCORING SYSTEM; STROKE; TREATMENT REFUSAL; VENOUS THROMBOEMBOLISM; VITAMIN INTAKE;

EID: 79959721098     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2011.04.001     Document Type: Review

References (30)

1. Inoue H., Fujiki A., Origasa H., Ogawa S., Okumura K., Kubota I., Aizawa Y., Yamashita T., Atarashi H., Horie M., Ohe T., Doi Y., Shimizu A., Chishaki A., Saikawa T., et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol 2009, 137:102-107.
2. Ohsawa M., Okayama A., Sakata K., Kato K., Itai K., Onoda T., Ueshima H. Rapid increase in estimated number of persons with atrial fibrillation in Japan: and analysis from national surveys on cardiovascular diseases in 1980, 1990 and 2000. J Epidemiol 2005, 15:194-196.
3. Kannel W.B, Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and. predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
4. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation 1998, 98:946-952.
5. Lin H.J., Wolf P.A., Kelly-Hayes M., Beiser A.S., Kase C.S., Benjamin E.J., D'Agostino R.B. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996, 27:1760-1764.
6. Wyse D.G., Waldo A.L., DiMarco J.P., Domanski M.J., Rosenberg Y., Schron E.B., Kellen J.C., Greene H.L., Mickel M.C., Dalquist J.E., Corley S.D. Atrial fibrillation follow-up investigation of rhythm management (AFFIRM) investigators, a comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
7. Van Gelder I.C., Hagens V.E., Bosker H.A., Kingma J.H., Kamp O., Kingma T., Said S.A., Darmanata J.I., Timmermans A.J., Tijssen J.G., Crijns H.J. Rate control versus electrical cardioversion for persistent atrial fibrillation study group, a comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002, 347:1834-1840.
8. Ogawa S., Yamashita T., Yamazaki T., Aizawa Y., Atarashi H., Inoue H., Ohe T., Ohtsu H., Okumura K., Katoh T., Kamakura S., Kumagai K., Kurachi Y., Kodama I., Koretsune Y., et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM study. Circ J 2009, 73:242-248.
9. Reynolds M.W., Fahrbach K., Hauch O., Wygant G., Estok R., Cella C., Nalysnyk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004, 126:1938-1945.
10. Gage B.F., van Walraven C., Pearce L., Hart R.G., Koudstaal P.J., Boode B.S., Petersen P. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110:2287-2292.
11. Lip G.Y., Edwards S.J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006, 118:321-333.
12. Miyasaka Y., Barnes M.E., Gersh B.J., Cha S.S., Seward J.B., Bailey K.R., Iwasaka T., Tsang T.S. Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005, 36:2362-2366.
13. Ogilvie I.M., Newton N., Welner S.A., Cowell W., Lip G.Y. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010, 123:638-645.
14. Suzuki S., Yamashita T., Ohtsuka T., Sagara K., Uejima T., Oikawa Y., Yajima J., Koike A., Nagashima K., Kirigaya H., Ogasawara K., Sawada H., Aizawa T. Prevalence and prognosis of patients with atrial fibrillation in Japan: a prospective cohort of Shinken database 2004. Circ J 2008, 72:914-920.
15. Inoue H., Nozawa T., Okumura K., Iwasa A., Lee J.D., Shimizu A., Hayano M., Yano K. Attitudes of Japanese cardiologists toward anticoagulation for nonvalvular atrial fibrillation and reasons for its underuse. Circ J 2004, 68:417-421.
16. Ezekowitz M.D., Aikens T.H., Brown A., Ellis Z. The evolving field of stroke prevention in patients with atrial fibrillation. Stroke 2010, 41(Suppl.):S17-20.
17. Escobar C., Barrios V., Jimenez D. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?. Cardiovasc Ther 2010, 28:295-301.
18. Bereznicki L.R., Peterson G.M. New antithrombotics for atrial fibrillation. Cardiovasc Ther 2010, 28:278-286.
19. Ahrens I., Lip G.Y., Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010, 104:49-60.
20. Piccini J.P., Lopes R.D., Mahaffey K.W. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 2010, 25:312-320.
21. Verheugt F.W. Novel oral anticoagulants to prevent stroke in atrial fibrillation. Nat Rev Cardiol 2010, 7:149-154.
22. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood 2010, 115:15-20.
23. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
24. Yasaka M., Minematsu K., Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern Med 2001, 40:1183-1188.
25. Odén A., Fahlén M., Hart R.G. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006, 117:493-499.
26. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, ESC Committee for Practice Guidelines Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010, 12. pp. 1360-420.
27. Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., Flaker G., Avezum A., Hohnloser S.H., Diaz R., Talajic M., Zhu J., Pais P., Budaj A., Parkhomenko A., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
28. Ruff C.T., Giugliano R.P., Antman E.M., Crugnale S.E., Bocanegra T., Mercuri M., Hanyok J., Patel I., Shi M., Salazar D., McCabe C.H., Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
29. Raskob G., Cohen A.T., Eriksson B.I., Puskas D., Shi M., Bocanegra T., Weitz J.I. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement, a randomised double-blind dose-response study. Thromb Haemost 2010, 104:642-649.
30. Ansell J. Warfarin versus new agents: interpreting the data. Hematol Am Soc Hematol Educ Prog 2010, 2010:221-228.